No announcement yet.

MSVirtual2020: Circuit exercising shows "significant improvement" in MS fatigue, walking

  • Filter
  • Time
  • Show
Clear All
new posts

  • MSVirtual2020: Circuit exercising shows "significant improvement" in MS fatigue, walking

    P1088 - Circuit class therapy in patients with Relapsing-Remitting Multiple Sclerosis (ID 697)

    J. Kolcava
    J. Kolcava J. Kočica M. Musilova F. Dosbaba J. Kratochvílová D. Krizova P. Stourac
    Presentation Number
    Presentation Topic
    Rehabilitation and Comprehensive Care



    Physiotherapy plays an essential part in the long-term multidisciplinary management in patients with Multiple Sclerosis (MS) and has shown to be beneficial in improving gait impairment and alleviating fatigue. Unfortunately, patients with MS have substantially lower physical activity among the general population. Therefore, interventions that can help to prevent disease progression are needed.

    Our study aimed to assess the efficacy of 12-week intensive circuit class therapy (one hour a week) on walking and fatigue in forty-eight relapsing-remitting MS patients with lower disability (EDSS up to 4.5).

    Forty-eight MS patient treated with DMDs were divided into two groups:

    Twenty-four patients underwent 12-week circuit class therapy (1 hour once a week). Mean EDSS 2.4 ± 0.79.

    Twenty-four patients as a control group. Mean EDSS 2.02 ± 0.62.

    Patients were assessed before and one week after 12-week circuit class therapy by clinical tests - EDSS (Expanded Disability Status Scale), TUG (Timed Up and Go) test, and multiple questionnaires - MFIS (Modified Fatigue Impact Scale) and MSWS-12 (12-item Multiple Sclerosis Walking Scale). The control group was assessed on routine controls on the baseline and after 12 weeks.

    Significant improvement was found in the TUG test in the therapy group, which was 927.3 ± 194.4 ms before and 814.8 ± 159.3 ms after the therapy (p<0.001). No significant improvement was found in the control group before (899.8 ± 144.4) and after 12 weeks (897.9 ± 145.4) (p=0.8).

    Improvement was found in MSWS-12 in the therapy group (before 18.6 ± 6.7; after 16.9 ± 6.3; p=0.04). No significant difference was found in the control group before (17.7 ± 5.6) and after 12 weeks (18.2 ± 5.4) (p=0.37).

    Improvement was found in MFIS in the therapy group (before 28.2 ± 15.5; after 22.4 ± 14.4; p=0.002). No significant difference was found in the control group before (25.7 ± 17.0) and after 12 weeks (25.4 ± 16.0) (p=0.73).

    The study showed significant improvement in the TUG test, MFIS, and MSWS-12 in the patients with RRMS after 12-weeks of intensive circuit class therapy, whereas the control group of relapsing-remitting MS patients did not show any significant improvement in the test and questionnaires.
    Dave Bexfield